Author/Authors :
Esmaeilidooki، Mohammad Reza نويسنده Non-Communicable Pediatric Diseases Research Center, Department of Pediatric, Babol University of Medical Sciences, Babol, IR Iran , , Moslemi، Leila نويسنده Department of Midwifery, Islamic Azad university, Sari Branch, Sari, Iran Moslemi, Leila , Rezai، Atena نويسنده Non-Communicable Pediatric Diseases Research Center, Department of Pediatric, Babol University of Medical Sciences, Babol, IR Iran , , Tirtashi، Morteza Safari نويسنده Non-Communicable Pediatric Diseases Research Center, Department of Pediatric, Babol University of Medical Sciences, Babol, IR Iran , , Sharbatdaran ، Majid نويسنده Department of Pathology, Babol University of Medical Sciences, Babol, Iran. , , Bijani ، Ali نويسنده Non-Communicable Pediatric Diseases Research Center, Babol University of Medical Sciences, Babol, Iran , , Njafi Sani، Mehri نويسنده Department of Pediatrics, Tehran University of Medical Sciences, Tehran, IR Iran , , Karami، Hassan نويسنده , , Pornasrollah، Mohammad نويسنده Non-Communicable Pediatric Diseases Research Center, Department of Pediatric, Babol University of Medical Sciences, Babol, IR Iran ,
Abstract :
Epidemiology of hepatitis A virus (HAV) is changing over time. Giving awareness of this issue can be developed as a plan to prevent complications of the disease; it is especially very helpful in high risk children, such as those with chronic liver disease. The current study aimed to investigate the seroprevalenceof anti-HAV antibodies in children with and without chronic liver diseases during two different periods. Two studies were conducted on anti-HAV seroprevalence antibodies in children aged one to fifteen years who were referred to Amirkola Children’s Hospital (Babol, North of Iran). The first study was conducted on 73 patients with chronic liver disease (CLD) in 2006, and the second study on 180 cases without it (NCLD) in 2011. Blood samples were collected from children and the sera were evaluated for anti-HAV antibodies via ELISA assay by Dia. Pro kit. Seroprevalence of HAV was 17.8% and 10% in the first and second study, respectively. There was no significant difference in age, sex, and place of residence between anti-HAV negative and positive subjects in the studies. It appears that anti-HAV antibody seroprevalence has declined among children below 15 years with and without chronic liver disease, and it is likely that more children would be susceptible to HAV infection. Therefore, it is important to employ preventative strategies against HAV in chronic liver diseases.
